Bringing telehealth to expectant mothers that will rival major hospital facilities, medtech company HeraMED (ASX: HMD) is taking a significant step forward in the commercialisation of their foetal monitoring device. As part of their Technology as a Service (TaaS) recurring revenue model, the Company has entered into an agreement with Joondalup Health Campus (JHC) which
Read More
Prior to COVID-19 bringing attention to the value of telehealth, HeraMED (ASX: HMD) has been building digital infrastructure to revolutionise the maternal healthcare market with their screening and remote midwife platform which is preparing to now enter the lucrative U.S market. The expansion into the world’s most lucrative healthcare market, valued at USD $111 billion
Read More
Medtech company HeraMED (ASX: HMD) has seen a major spike in investor confidence after securing clearance from the US Food and Drug Administration (FDA) for HeraBEAT US – their fetal ultrasonic heart monitor. Intended to detect, display and replay heart beats from as early as 12 weeks into pregnancy, the handheld device was developed in
Read More
Technology developer HeraMed (ASX: HMD) has continued its progression into the Indian market with its pregnancy monitoring devices aimed at improving engagement between pregnant women and medical professionals to improve health monitoring and early risk detection. The progress sees an extension of a Memorandum of Understanding with Indian distributors Consultus India as well as a
Read More